Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900408 | 0.92 | HSP90AA1 (0.42) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL6747599 | 0.89 | HSP90AA1 (0.49) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL5130730 | 0.83 | MAPT (0.45) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL11900055 | 0.81 | HSP90AA1 (0.45) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL6747590 | 0.80 | HSP90AA1 (0.50) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL11900631 | 0.80 | PDCD1 (0.42) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL3918995 | 0.79 | HSP90AA1 (0.51) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL11900837 | 0.78 | MAPT (0.46) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL11900779 | 0.75 | HSP90AA1 (0.46) | HSP90AA1MAPTPDK1HSP90B1TRAP1 | |
| SCHEMBL3995575 | 0.75 | CHRM4 (0.39) | HSP90AA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | claimed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | claimed |
| US-8183384-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-05-22 | — | — | US | claimed |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329736-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202813-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885MAPT 2927/4885PDK1 1567/4885 |
| US-20130072461-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885MAPT 2927/4885PDK1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.